KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Cash from Financing Activities (2017 - 2026)

Aquestive Therapeutics has reported Cash from Financing Activities over the past 9 years, most recently at $660000.0 for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 320.38% year-over-year to $660000.0; the TTM value through Dec 2025 reached $102.6 million, up 22.76%, while the annual FY2025 figure was $102.6 million, 22.76% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was $660000.0 at Aquestive Therapeutics, down from $81.4 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $81.7 million in Q1 2024 and troughed at -$9.2 million in Q1 2023.
  • A 5-year average of $11.6 million and a median of $4.1 million in 2023 define the central range for Cash from Financing Activities.
  • Biggest five-year swings in Cash from Financing Activities: plummeted 809.17% in 2023 and later soared 478988.24% in 2025.
  • Year by year, Cash from Financing Activities stood at $5.5 million in 2021, then tumbled by 95.71% to $234000.0 in 2022, then skyrocketed by 1572.22% to $3.9 million in 2023, then plummeted by 95.99% to $157000.0 in 2024, then skyrocketed by 320.38% to $660000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for AQST at $660000.0 in Q4 2025, $81.4 million in Q3 2025, and -$100000.0 in Q2 2025.